DRTS

6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

- IDE supplement expands trial to the other primary standard-of-care chemotherapy for pancreatic cancer patients, alongside mFOLFIRINOX - - IDE supplement also expands total trial size from 30 to 40 patients - - Study explores Alpha DaRT combined with chemotherapy in patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma - - This pilot study is a key part of Alpha Tau's broader strategy to bring Alpha DaRT to cancer patients with some of the highest unmet needs - JERUSALEM, April 23, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alp

ACAPELLA is the European multicenter clinical trial evaluating Alpha DaRT alpha-emitter radiotherapeutics combined with capecitabine for inoperable LAPC patients who have completed first-line mFOLFIRINOX, a population for whom no standard consolidation therapy exists and whose prognosis remains poor despite completing the best available systemic treatmentApproximately 30% of the estimated 140,000 Europeans diagnosed with pancreatic cancer each year present with locally advanced, inoperable, non-metastatic diseaseThe trial is a key pillar of Alpha Tau's global clinical expansion strategy in Europe, alongside the ongoing IMPACT multicenter pancreatic cancer trial in the United States First pat

6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

JERUSALEM, March 31, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that an abstract presenting results of two clinical trials in Jerusalem in patients with pancreatic cancer has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026, the world's premier international gastroenterology conference. This marks the first time that clinical results of Alpha DaRT in pancreatic cancer patients have been selected for presentation at a major gastroenterology conference. The abstract, entitled "Updated Results of Feasibility, Safety, and Tumor Control

3 - Alpha Tau Medical Ltd. (0001871321) (Issuer)

3 - Alpha Tau Medical Ltd. (0001871321) (Issuer)

3 - Alpha Tau Medical Ltd. (0001871321) (Issuer)

3 - Alpha Tau Medical Ltd. (0001871321) (Issuer)

3 - Alpha Tau Medical Ltd. (0001871321) (Issuer)

3 - Alpha Tau Medical Ltd. (0001871321) (Issuer)

3 - Alpha Tau Medical Ltd. (0001871321) (Issuer)

3 - Alpha Tau Medical Ltd. (0001871321) (Issuer)

3 - Alpha Tau Medical Ltd. (0001871321) (Issuer)

JERUSALEM, March 16, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference taking place on March 18-19, 2026. Event:Sidoti Virtual Small Cap ConferenceFormat:Company PresentationDate:March 18, 2026Time:10:00 – 10:30AM ETLocation:Virtual Mr. Levy will be available for 1x1 investor meetings at the conference. Please reach out to your Sidoti representative to schedule. About Alpha Tau Medical Ltd.  Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, de

S-8 - Alpha Tau Medical Ltd. (0001871321) (Filer)

20-F - Alpha Tau Medical Ltd. (0001871321) (Filer)

6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment - - Multiple meaningful milestones targeted in the coming months, including completion of patient recruitment in the U.S. pivotal ReSTART skin cancer trial, in the U.S. pilot IMPACT pancreatic cancer trial, and in the U.S. recurrent glioblastoma multiforme feasibility trial - - $76.9 million in cash, cash equivalents & deposits provides continued balance sheet strength for clinical advancement and commercial preparation - JERUSALEM, March 09, 2026 (GLOBE NE

Piper Sandler downgraded Alpha Tau from Overweight to Neutral and set a new price target of $5.00

144 - Alpha Tau Medical Ltd. (0001871321) (Subject)

6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

- Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program - - First-in-kind technology delivers intra-tumoral alpha-emitting radiotherapeutics, reflects strength of clinical data and strong collaboration with Japanese regulators and clinical societies - JERUSALEM, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that Japan's Ministry of Health, Labour and Welfare ("MHLW") has granted regulatory (Shonin) marketing approval for Alpha DaRT for the treatment of unresectable locally advanced or locally

6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in cancers of internal organs including the pancreas and brain - - Ramping U.S. manufacturing for commercial readiness - Jerusalem, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today issued the following letter to shareholders: Dear Shareholders, Following an incredibly productive 2025, culminating in several significant announcements in recent weeks, I wish to sha